Biogenic Aldehydes as Therapeutic Targets for Cardiovascular Disease

Margaret-Ann M Nelson; Shahid P Baba; Ethan J Anderson

doi:10.1016/j.coph.2017.04.004

Back

Biogenic Aldehydes as Therapeutic Targets for Cardiovascular Disease

Journal article

Open access

Peer reviewed

Biogenic Aldehydes as Therapeutic Targets for Cardiovascular Disease

Margaret-Ann M Nelson, Shahid P Baba and Ethan J Anderson

Current opinion in pharmacology, Vol.33, pp.56-63

04/2017

DOI: 10.1016/j.coph.2017.04.004

PMCID: PMC5563970

PMID: 28528297

Files and links (1)

url

https://www.ncbi.nlm.nih.gov/pmc/articles/5563970View

Open Access

Abstract

Aldehydes are continuously formed in biological systems through enzyme-dependent and spontaneous oxidation of lipids, glucose, and primary amines. These highly reactive, biogenic electrophiles can become toxic via covalent modification of proteins, lipids and DNA. Thus, agents that scavenge aldehydes through conjugation have therapeutic value for a number of major cardiovascular diseases. Several commonly-prescribed drugs (e.g., hydralazine) have been shown to have potent aldehyde-conjugating properties which may contribute to their beneficial effects. Herein, we briefly describe the major sources and toxicities of biogenic aldehydes in cardiovascular system, and provide an overview of drugs that are known to have aldehyde-conjugating effects. Some compounds of phytochemical origin, and histidyl-dipeptides with emerging therapeutic value in this area are also discussed.

Animals

Dipeptides - therapeutic use

Phytochemicals - therapeutic use

Aldehydes - pharmacology

Cardiovascular Diseases - drug therapy

Dipeptides - pharmacology

Humans

Oxidation-Reduction - drug effects

Aldehydes - therapeutic use

Phytochemicals - pharmacology

Details

Title: Subtitle: Biogenic Aldehydes as Therapeutic Targets for Cardiovascular Disease
Creators: Margaret-Ann M Nelson - Department of Pharmacology & Toxicology, East Carolina University, Greenville, NC, USA
Shahid P Baba - Department of Medicine, Diabetes and Obesity Center, University of Louisville, Louisville, KY, USA
Ethan J Anderson - Department of Pharmaceutical Sciences & Experimental Therapeutics, College of Pharmacy, Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA, USA. Electronic address: ethan-anderson@uiowa.edu
Resource Type: Journal article
Publication Details: Current opinion in pharmacology, Vol.33, pp.56-63
DOI: 10.1016/j.coph.2017.04.004
PMID: 28528297
PMCID: PMC5563970
NLM abbreviation: Curr Opin Pharmacol
ISSN: 1471-4892
eISSN: 1471-4973
Publisher: England
Grant note: R01 HL122581 / NHLBI NIH HHS R01 HL122863 / NHLBI NIH HHS R21 AG057006 / NIA NIH HHS
Language: English
Date published: 04/2017
Academic Unit: Pharmaceutical Sciences and Experimental Therapeutics; Fraternal Order of Eagles Diabetes Research Center; Health, Sport, and Human Physiology
Record Identifier: 9984065318002771

Metrics

30 Record Views

21 Times Cited - Web of Science